Present Constraints on the H-dibaryon at the Physical Point from Lattice QCD

The current constraints from lattice QCD on the existence of the H-dibaryon are discussed. With only two significant lattice QCD calculations of the H-dibaryon binding energy at approximately the same lattice spacing, the forms of the chiral and continuum extrapolations to the physical point are not determined. In this brief report, we consider the constraints on the H-dibaryon imposed by two simple chiral extrapolations. In both instances, the extrapolation to the physical pion mass allows for a bound H-dibaryon or a near-threshold scattering state. Further lattice QCD calculations are required to clarify this situation.Comment: 8 pages, 2 figures, 1 table; revised for the journa

High Statistics Analysis using Anisotropic Clover Lattices: (IV) Volume Dependence of Light Hadron Masses

The volume dependence of the octet baryon masses and relations among them are explored with Lattice QCD. Calculations are performed with n_f=2+1 clover fermion discretization in four lattice volumes, with spatial extent L ~ 2.0, 2.5, 3.0 and 3.9 fm, with an anisotropic lattice spacing of b_s ~ 0.123 fm in the spatial direction, and b_t = b_s/3.5 in the time direction, and at a pion mass of m_pi ~ 390 MeV. The typical precision of the ground-state baryon mass determination is ~0.2%, enabling a precise exploration of the volume dependence of the masses, the Gell-Mann--Okubo mass relation, and of other mass combinations. A comparison of the volume dependence with the predictions of heavy baryon chiral perturbation theory is performed in both the SU(2)_L X SU(2)_R and SU(3)_L X SU(3)_R expansions. Predictions of the three-flavor expansion for the hadron masses are found to describe the observed volume dependences reasonably well. Further, the Delta-N-pi axial coupling constant is extracted from the volume dependence of the nucleon mass in the two-flavor expansion, with only small modifications in the three-flavor expansion from the inclusion of kaons and etas. At a given value of m_pi L, the finite-volume contributions to the nucleon mass are predicted to be significantly smaller at m_pi ~ 140 MeV than at m_pi ~ 390 MeV due to a coefficient that scales as ~ m_pi^3. This is relevant for the design of future ensembles of lattice gauge-field configurations. Finally, the volume dependence of the pion and kaon masses are analyzed with two-flavor and three-flavor chiral perturbation theory.Comment: 34 pages, 45 figure

Nucleon mass and pion-nucleon sigma term from a chiral analysis of lattice QCD data

The pion mass dependence of the nucleon mass within the covariant SU(2) baryon chiral perturbation theory both without and with explicit Delta(1232) degrees of freedom up to order p(4) is investigated. By fitting to a comprehensive set of lattice QCD data in 2 and 2 + 1 flavors from several collaborations, for pion masses M-pi < 420 MeV, we obtain low energy constants of natural size that are compatible with pion-nucleon scattering data. Our results are consistent with the rather linear pion mass dependence showed by lattice QCD. In the 2 flavor case we have also performed simultaneous fits to nucleon mass and sigma(pi N) data. As a result of our analysis, which encompasses the study of finite volume corrections and discretization effects, we report a value of sigma(pi N) = 41(5)(4) MeV in the 2 flavor case and sigma(pi N) = 52(3)(8) MeV for 2 + 1 flavors, where the inclusion of the Delta(1232) resonance changes the results by around 9 MeV. In the 2 flavor case we are able to set independently the scale for lattice QCD data, given by a Sommer scale of r(0) = 0.493(23) fm

Light Nuclei and Hypernuclei from Quantum Chromodynamics in the Limit of SU(3) Flavor Symmetry

The binding energies of a range of nuclei and hypernuclei with atomic number A <= 4 and strangeness |s| <= 2, including the deuteron, di-neutron, H-dibaryon, 3He, Lambda 3He, Lambda 4He, and Lambda Lambda 4He, are calculated in the limit of flavor-SU(3) symmetry at the physical strange quark mass with quantum chromodynamics (without electromagnetic interactions). The nuclear states are extracted from Lattice QCD calculations performed with n_f=3 dynamical light quarks using an isotropic clover discretization of the quark-action in three lattice volumes of spatial extent L ~ 3.4 fm, 4.5 fm and 6.7 fm, and with a single lattice spacing b ~ 0.145 fm.Comment: 35 pages, 45 figures Increased statistics, enhanced discussion, fixed typo

Hadron Structure on the Lattice

A few chosen nucleon properties are described from a lattice QCD perspective: the nucleon sigma term and the scalar strangeness in the nucleon; the vector form factors in the nucleon, including the vector strangeness contribution, as well as parity breaking effects like the anapole and electric dipole moment; and finally the axial and tensor charges of the nucleon. The status of the lattice calculations is presented and their potential impact on phenomenology is discussed.Comment: 17 pages, 9 figures; proceedings of the Conclusive Symposium of the Collaborative Research Center 443 "Many-body structure of strongly interacting systems", Mainz, February 23-25, 201

Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer

<p>Abstract</p> <p>Background</p> <p>Ductal lavage (DL) has been proposed as a minimally-invasive, well-tolerated tool for obtaining breast epithelial cells for cytological evaluation of breast cancer risk. We report DL tolerability in <it>BRCA1/2 </it>mutation-positive and -negative women from an IRB-approved research study.</p> <p>Methods</p> <p>165 <it>BRCA1/2 </it>mutation-positive, 26 mutation-negative and 3 mutation unknown women underwent mammography, breast MRI and DL. Psychological well-being and perceptions of pain were obtained before and after DL, and compared with pain experienced during other screening procedures.</p> <p>Results</p> <p>The average <b><it>anticipated </it></b>and <b><it>experienced </it></b>discomfort rating for DL, 47 and 48 (0–100), were significantly higher (<it>p </it>< 0.01) than the <b><it>anticipated </it></b>and <b><it>experienced </it></b>discomfort of mammogram (38 and 34), MRI (36 and 25) or nipple aspiration (42 and 27). Women with greater pre-existing emotional distress experienced more DL-related discomfort than they anticipated. Women reporting DL-related pain as worse than expected were nearly three times more likely to refuse subsequent DL than those reporting it as the same or better than expected. Twenty-five percent of participants refused repeat DL at first annual follow-up.</p> <p>Conclusion</p> <p>DL was anticipated to be and experienced as <b>more </b>uncomfortable than other procedures used in breast cancer screening. Higher underlying psychological distress was associated with decreased DL tolerability.</p

Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney disease

When assessing changes in glomerular filtration rate (GFR) it is important to differentiate pathological change from intrinsic biological and analytical variation. GFR is measured using complex reference methods (e.g. iohexol clearance). In clinical practice measurement of creatinine and cystatin C is used in equations (e.g. Modification of Diet in Renal Disease [MDRD] or Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) to provide estimated GFR. We studied biological variability of measured and estimated GFR in twenty nephrology outpatients (10 male, 10 female; median age 71, range 50-80 years) with moderate CKD (GFR 30-59 mL/min/1.73 m2). Patients underwent weekly GFR measurement by iohexol clearance over four consecutive weeks. Simultaneously GFR was estimated using the MDRD, CKD-EPIcreatinine, CKD-EPIcystatinC and CKD-EPIcreatinine+cystatinC equations. Within-subject biological variation (CVI) expressed as a percentage [95% CI] for the MDRD (5.0% [4.3-6.1]), CKD-EPIcreatinine (5.3% [4.5-6.4]), CKD-EPIcystatinC (5.3% [4.5-6.5]), and CKD-EPIcreatinine+cystatinC (5.0% [4.3-6.2]) equations were broadly equivalent. CVI values for MDRD and CKD- EPIcreatinine+cystatinC were lower (p=0.027 and p=0.022 respectively) than that of measured GFR (6.7% [5.6-8.2]). Reference change values (RCV), the point at which a true change in a biomarker in an individual can be inferred to have occurred with 95% probability were calculated: using the MDRD equation, positive and negative RCVs were 15.1% and 13.1% respectively. If an individual’s baseline MDRD estimated GFR (mL/min/1.73 m2) was 59, significant increases or decreases would be to values >68 or <51 respectively. Within-subject variability of estimated GFR is lower than measured GFR. RCVs can be used to understand GFR changes in clinical practice

Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer

<p>Abstract</p> <p>Background</p> <p>Complementary and alternative medicine (CAM) use is well documented among breast cancer patients and survivors, but little evidence is available to describe rates and patterns of use among women at increased genetic risk of breast cancer.</p> <p>Methods</p> <p>A pre-visit telephone interview was conducted to ascertain CAM use among the <it>BRCA </it>mutation carriers enrolled in a high-risk breast cancer screening study. Participants were asked to report on their use of thirteen therapies within the year prior to enrollment into the study. Logistic regression was used to evaluate the association between various factors and CAM use in this population.</p> <p>Results</p> <p>Among the 164 <it>BRCA1 </it>or <it>BRCA2 </it>mutation-positive (<it>BRCA</it>+) women in this analysis, 78% reported CAM use, with prayer and lifestyle diet being the two most commonly reported modalities. Many subjects used multiple CAM therapies, with 34% reporting use of three or more modalities. The most commonly used modalities were mind-body therapies and biologically-based practices, 61.6% and 51.8%, respectively. High-risk women were more likely to use CAM if they were older, more educated, more worried about ovarian cancer risk, or had a previous cancer diagnosis.</p> <p>Conclusion</p> <p>This study suggests that the prevalence of CAM use is high among <it>BRCA </it>mutation carriers, with frequency of use comparable to that of breast cancer patients and survivors. Given the high prevalence of CAM use in our subjects, especially biologically-based therapies including herbal supplements, whose safety and efficacy in relation to cancer risk are unknown, our study suggests that future research is necessary to clarify these risks, and that it is important for providers to inquire about and to discuss the pros and cons of CAM use with their <it>BRCA+ </it>patients.</p

BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers

Background: The K3326X variant in BRCA2 (BRCA2*c.9976A&gt;T; p.Lys3326*; rs11571833) has been found to be associated with small increased risks of breast cancer. However, it is not clear to what extent linkage disequilibrium with fully pathogenic mutations might account for this association. There is scant information about the effect of K3326X in other hormone-related cancers. Methods: Using weighted logistic regression, we analyzed data from the large iCOGS study including 76 637 cancer case patients and 83 796 control patients to estimate odds ratios (ORw) and 95% confidence intervals (CIs) for K3326X variant carriers in relation to breast, ovarian, and prostate cancer risks, with weights defined as probability of not having a pathogenic BRCA2 variant. Using Cox proportional hazards modeling, we also examined the associations of K3326X with breast and ovarian cancer risks among 7183 BRCA1 variant carriers. All statistical tests were two-sided. Results: The K3326X variant was associated with breast (ORw = 1.28, 95% CI = 1.17 to 1.40, P = 5.9x10- 6) and invasive ovarian cancer (ORw = 1.26, 95% CI = 1.10 to 1.43, P = 3.8x10-3). These associations were stronger for serous ovarian cancer and for estrogen receptor–negative breast cancer (ORw = 1.46, 95% CI = 1.2 to 1.70, P = 3.4x10-5 and ORw = 1.50, 95% CI = 1.28 to 1.76, P = 4.1x10-5, respectively). For BRCA1 mutation carriers, there was a statistically significant inverse association of the K3326X variant with risk of ovarian cancer (HR = 0.43, 95% CI = 0.22 to 0.84, P = .013) but no association with breast cancer. No association with prostate cancer was observed. Conclusions: Our study provides evidence that the K3326X variant is associated with risk of developing breast and ovarian cancers independent of other pathogenic variants in BRCA2. Further studies are needed to determine the biological mechanism of action responsible for these associations